Guttides is a wellness term for a blend or protocol involving BPC-157 and KPV, often marketed for gut inflammation or “gut repair.” The available support is mainly cell and animal research, not proven human benefit. Neither peptide is FDA-approved for gut healing, IBS, inflammatory bowel disease, weight loss, recovery, or longevity. 3
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What is Guttides, and why are people searching for BPC-157 and KPV?
Guttides appears to be a wellness-clinic or marketing term rather than a recognized drug name. It usually describes an investigational peptide blend built around BPC-157 and KPV, two compounds promoted online for intestinal-barrier, inflammation, and recovery claims. No FDA-approved product label exists for this blend. 3 5
The interest is understandable. Gut symptoms can affect daily life, and phrases such as “leaky gut” or “gut lining repair” can sound like a simple explanation. But those phrases are not a diagnosis. IBS, inflammatory bowel disease (IBD), infection, celiac disease, medication effects, and food-related symptoms can overlap, and they do not have the same evaluation or treatment path. 6 7
A mechanism is not the same as a clinical result. A peptide may change a cytokine signal in a cell dish or reduce inflammation in a rodent model without proving that it improves pain, bowel habits, inflammation, healing, or quality of life in people.
What are BPC-157 and KPV supposed to do?
BPC-157, short for body protection compound 157, is a synthetic peptide that has been investigated mostly in animal models of tissue injury and gastrointestinal injury. Its gut-related evidence remains preclinical. Reviews of the literature describe animal findings, but they do not establish BPC-157 as an effective treatment for human ulcerative colitis, Crohn’s disease, IBS, or intestinal injury. 2
KPV is Lys-Pro-Val, a tripeptide derived from alpha-MSH, also called alpha-melanocyte-stimulating hormone. Researchers have studied whether KPV can affect inflammatory signaling in intestinal epithelial cells and immune cells. Its short size and proposed activity have made it interesting for gut research, but it is not an approved treatment for a gut condition. 1
Online claims often connect these peptides to the mucosal barrier, immune balance, and recovery. Those are biological ideas under study, not established patient outcomes. The useful question is not only “what might this do in a model?” but also “what human condition was studied, against what comparison, for how long, and with what safety follow-up?”
What does the evidence say about KPV for gut inflammation?
KPV has a clearer preclinical gut-research story than a human clinical story. In laboratory and mouse colitis research, investigators reported that KPV uptake through the PepT1 transporter was associated with lower intestinal inflammatory activity. The key studies were published in 2008 and were not human treatment trials. 1
PepT1 is a transporter found in intestinal epithelial cells and some immune cells. In preclinical work, KPV has been linked with changes in NF-kB signaling, a pathway that helps control inflammatory gene activity. Researchers have also examined downstream signals such as TNF-alpha, IL-6, and IL-1 beta. These are useful clues about mechanism, but they do not show that KPV heals the gut in people. 1
That distinction matters most for people with IBD. Ulcerative colitis and Crohn’s disease can cause complications when inflammation is not controlled, and evidence-based care uses diagnosis, disease monitoring, and therapies studied in people with those conditions. 7
What does the evidence say about BPC-157 for gut healing?
BPC-157 is frequently discussed as a tissue-repair peptide, including for the gastrointestinal tract. Most cited gut findings come from animal experiments, not completed human outcome trials. 2
Animal studies are valuable for generating hypotheses. They can help researchers decide what to study next and how a compound might work. They cannot tell us whether a product improves human symptoms, whether it is safe over months or years, or whether it interacts with prescription medicines.
Product source is another concern. Products sold online as “research use only” are not the same as prescription care from a licensed clinician and pharmacy. FDA advises people buying medicine online to use licensed pharmacies and avoid unsafe online sources. 4 Our guide to finding a legitimate peptide source explains practical questions to ask about prescriptions, pharmacy licensing, and product handling.
3-min quiz
Questions about clinician-reviewed peptide care?
Chia does not offer Guttides or KPV. We do offer BPC-157 injection through an online evaluation when clinically appropriate. A prescription requires a licensed-provider review and is never guaranteed. Medications are compounded by US state-licensed 503A pharmacies; compounded drugs are not FDA-approved.
Can you take BPC-157 and KPV together?
BPC-157 and KPV together is an online combination claim, not an established combination therapy. There are no established human combination trials showing that a BPC-157/KPV blend is safe or effective for gut disease. 2 5
It is tempting to assume that two peptides with different proposed mechanisms will work better together. That assumption does not account for dose-finding, absorption, contamination risk, interactions, or unexpected effects. A blend should be tested as a blend; evidence for its individual ingredients does not prove the combination.
For a closer look at the evidence gaps, see our articles on KPV peptide research, BPC-157 and KPV side effects, and liposomal BPC-157 and KPV oral peptides.
Is Guttides safe, and who should avoid unapproved peptide blends?
Safety is unknown for Guttides as a combination. Long-term human safety data are not established. That includes questions about purity, actual peptide content, sterility for injectable products, contaminants, and how the blend may interact with other medicines. 4 5
People who are pregnant, breastfeeding, immunosuppressed, living with active cancer or a cancer history, managing liver or kidney disease, or taking prescription medicines should seek individualized advice from a qualified clinician before considering an unapproved peptide, because human safety and interaction data are limited. 2 5
- Seek urgent care for blood in stool, black stool, severe or worsening abdominal pain, fainting, confusion, or signs of severe dehydration. 8
- Arrange medical evaluation for ongoing diarrhea, fever, persistent vomiting, unexplained weight loss, anemia, or symptoms that wake you from sleep. 6 8
- Do not assume a suspected IBD flare, infection, or medication reaction is a “gut lining” problem that can be self-treated with a peptide. 7 8
How does Guttides compare with evidence-based gut care?
A diagnosis comes before an experimental treatment. IBS and IBD are different conditions with different care plans. A clinician may use symptoms, medication history, lab work, stool testing, imaging, or endoscopy when indicated to narrow down what is causing symptoms. 6 7
| Approach | What evidence supports it? | Key limitation or safety point |
|---|---|---|
| Guttides / BPC-157 / KPV blend | Cell and animal research suggests possible anti-inflammatory or tissue-response mechanisms. 1 2 | No established human combination evidence, approved indication, or FDA-approved dosing schedule. |
| IBS evaluation and guideline-based care | Professional guidance supports diagnosis based on symptom pattern and appropriate testing, followed by targeted care. 6 | Treatment depends on the dominant symptom pattern and other health conditions. |
| Ulcerative colitis or Crohn’s disease care | Human clinical evidence supports disease-specific monitoring and approved therapies for moderate to severe disease. 7 | Delaying evaluation can allow inflammation or complications to progress. |
| Licensed prescription and pharmacy pathway | FDA recommends using licensed healthcare professionals and pharmacies when obtaining prescription medicines online. 4 | A clinical evaluation is still needed; a prescription is not guaranteed. |
What peptide care does Chia offer, and what do we not offer?
Chia does not offer Guttides or KPV. We do offer BPC-157 injection through clinician-reviewed online care where clinically appropriate. Plans currently start at $145 per month. BPC-157 is not FDA-approved for gut healing or other uses discussed in this article, and a prescription is never guaranteed.
We also offer other clinician-reviewed compounded options with different intended care contexts: GHK-Cu cream, glutathione injection or nasal spray, NAD+ injection or nasal spray, PT-141 nasal spray, and sermorelin injection, nasal spray, or tablets. These are not substitutes for evaluating unexplained gut symptoms, and they should not be confused with Guttides.
At Chia, you complete a short online health questionnaire and a licensed US provider reviews it. When treatment is clinically appropriate, medication is compounded in the US by a state-licensed 503A pharmacy and shipped to your door. Providers guide dosing and follow-up through the patient portal. Compounded medications are not FDA-approved.
What should you ask a clinician before considering any gut peptide?
The first question is what condition is being treated. A careful evaluation can prevent months of self-treatment for the wrong problem. Bring a clear symptom timeline, a list of medications and supplements, and any prior testing to your visit. 6 7
- 1What diagnosis are we considering, and what else needs to be ruled out?
- 2Is there human evidence for this peptide in people with my specific condition?
- 3Is the product FDA-approved, compounded, or sold as a research chemical?
- 4What are the known side effects, unknowns, interactions, and reasons not to use it?
- 5What monitoring and follow-up would be needed if treatment is considered?
3-min quiz
Start with a licensed clinical review
If you are exploring peptide care, our providers can review your goals and health history online. Chia does not offer Guttides or KPV, and a prescription requires a medical evaluation and is not guaranteed. Learn about BPC-157 injection care or begin with our eligibility quiz.
Frequently asked questions about Guttides, BPC-157, and KPV
There is no good human clinical evidence showing that KPV heals the gut. KPV has been studied in cells and animal models of intestinal inflammation, but those findings do not prove it treats IBS, IBD, or intestinal-barrier problems in people. 1
Because human safety information is limited, people who are pregnant, breastfeeding, immunosuppressed, managing cancer or a cancer history, living with significant liver or kidney disease, or taking prescription medicines should seek individualized advice from a clinician before considering an unapproved peptide. 2 5
Use a licensed healthcare provider and a state-licensed pharmacy for prescription care. Avoid relying on unlicensed sellers that market injectable or oral products as research chemicals. 4 Chia offers online, clinician-reviewed care for selected treatments in our current catalog, including BPC-157 injection where clinically appropriate.
References
- 1.Dalmasso G, Charrier-Hisamuddin L, Thu Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
- 2.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011.
- 3.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. 2025.
- 4.U.S. Food and Drug Administration. BeSafeRx: Know Your Online Pharmacy. FDA. 2025.
- 5.U.S. Food and Drug Administration. The Drug Development Process. FDA. 2018.
- 6.Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2021.
- 7.Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020.
- 8.National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Inflammatory Bowel Disease. National Institutes of Health. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
